Login to Your Account

Clinic Roundup

Wednesday, February 2, 2011
Medicago Inc., of Quebec City, reported interim results from a Phase II trial of its H5N1 avian influenza virus-like particle vaccine candidate, showing that it was safe, well tolerated and induced a solid immune response.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription